Author details

Full Name

Mark Marriott

Affiliation

ORCID

Career Start Year

2002

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
38043368	Neutropaenia complications from Ocrelizumab and Rituximab treatment.		2023
35216788	Response to treatment in NMOSD: the Australasian experience.	Multiple Sclerosis and Related Disorders	2022
35661564	Impact of telehealth on health care in a multiple sclerosis outpatient clinic during the COVID-19 pandemic.	Multiple Sclerosis and Related Disorders	2022
35264149	Failure of alemtuzumab therapy in three patients with MOG antibody associated disease.	BMC Neurology	2022
34566866	MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis.	Front Neurol	2021
33847902	Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study.	CNS Drugs	2021
32612571	Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation.	Front Neurol	2020
32006158	The clinical profile of NMOSD in Australia and New Zealand.	J Neurol	2020
31877445	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.	Multiple Sclerosis and Related Disorders	2020
32957057	Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia.	Multiple Sclerosis and Related Disorders	2020
28550069	Incidence and prevalence of NMOSD in Australia and New Zealand.	J Neurol Neurosurg Psychiatry	2017
28347683	Adult food borne botulism in Australia: The only 2 cases from the last 15years.	Journal of Clinical Neuroscience	2017
26209918	Cervical CT scan-guided epidural blood patches for spontaneous intracranial hypotension.	Journal of Clinical Neuroscience	2015
25639936	Galanin is an autocrine myelin and oligodendrocyte trophic signal induced by leukemia inhibitory factor.	GLIA	2015
26014602	The occurrence of dystonia in upper-limb multiple sclerosis tremor.	Multiple Sclerosis Journal	2015
26224184	A new era in the treatment of multiple sclerosis.	Med J Aust	2015
24986155	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.	J Clin Neurosci	2014
24993136	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists.	J Clin Neurosci	2014
24993135	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists.	J Clin Neurosci	2014
24386285	Optic nerve diffusion tensor imaging after acute optic neuritis predicts axonal and visual outcomes.	PLoS One	2013
22247457	Diffusion tensor imaging correlates of visual impairment in multiple sclerosis and chronic optic neuritis.	Invest Ophthalmol Vis Sci	2012
22753445	A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor.	Neurology	2012
21833088	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.	Nature	2011
22190364	Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.	Ann Neurol	2011
20122960	Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade.	Pharmacol Ther	2010
19324983	Re: early relapses after the first dose of natalizumab in active multiple sclerosis.	Multiple Sclerosis Journal	2009
19392788	HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis.		2009
18650830	Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians.	Genes and Immunity	2008
17968901	MRI identification of the rostral-caudal pattern of pathology within the corpus callosum in the cuprizone mouse model.	J Magn Reson Imaging	2008
18293407	Leukemia inhibitory factor signaling modulates both central nervous system demyelination and myelin repair.	Glia	2008
16498619	Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss.	GLIA	2006
16682639	Suppressor of cytokine signaling 3 limits protection of leukemia inhibitory factor receptor signaling against central demyelination.	Proceedings of the National Academy of Sciences of the United States of America	2006
15014978	Extended haplotype analysis in the HLA complex reveals an increased frequency of the HFE-C282Y mutation in individuals with multiple sclerosis.	Human Genetics	2004
15326616	Expression of the low-affinity neurotrophin receptor, p75(NTR), is upregulated by oligodendroglial progenitors adjacent to the subventricular zone in response to demyelination.	GLIA	2004
15853513	Neuroglial responses to CNS injury: prospects for novel therapeutics.	Expert Review of Neurotherapeutics	2004
12453844	Flail arms in a parachutist: an unusual presentation of hereditary neuropathy with liability to pressure palsies.	British Journal of Sports Medicine	2002